Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조영주 | * |
dc.date.accessioned | 2018-12-07T16:30:38Z | - |
dc.date.available | 2018-12-07T16:30:38Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 1471-2466 | * |
dc.identifier.other | OAK-20703 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247377 | - |
dc.description.abstract | Background: To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in Asian patients. Methods: A post hoc analysis of the GOAL study in which patients were stratified by prior-medication use into inhaled corticosteroid (ICS)-naïve (Stratum [S] 1), low-dose ICS (S2), and medium-dose ICS (S3), and randomised to receive FP/SAL or FP. Doses were stepped-up every 12 weeks until Totally Controlled asthma or maximum dose was reached (PhI) and then maintained until study end (PhII). The primary endpoint was the proportion of patients achieving Well-Controlled asthma during PhI. Additional endpoints included Total Control and adverse events. Asian and non-Asian patients were analysed separately. Results: In Asian patients in PhI, 74% (n = 87/118) in S1 achieved Well-Controlled asthma with FP/SAL versus 74% (n = 89/121) with FP alone (p = 0.839); corresponding values were 76% (n = 81/107) versus 60% (n = 62/104; p = 0.005) in S2, and 58% (n = 59/102) versus 43% (n = 41/95; p = 0.015) in S3. More patients in all three strata achieved Totally Controlled asthma with FP/SAL versus FP alone. Control was achieved more rapidly and with lower ICS doses with FP/SAL versus FP. A high proportion of patients who achieved control during PhI maintained control during PhII. Similar trends were found in non-Asian patients. No new safety concerns were identified. Conclusions: A greater proportion of Asian patients (S2 and S3, for Well-Controlled; all strata, for Totally Controlled) achieved guideline-defined asthma control with FP/SAL versus FP alone. High proportions of Asian patients in S1 achieved Well-Controlled asthma in both treatment groups. © 2017 The Author(s). | * |
dc.language | English | * |
dc.publisher | BioMed Central Ltd. | * |
dc.subject | Asian patients | * |
dc.subject | Asthma | * |
dc.subject | Asthma control | * |
dc.subject | Asthma treatment | * |
dc.subject | Fluticasone propionate/salmeterol | * |
dc.subject | ICS/LABA treatment | * |
dc.title | Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: A post hoc analysis of the GOAL study | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 17 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | BMC Pulmonary Medicine | * |
dc.identifier.doi | 10.1186/s12890-017-0410-x | * |
dc.identifier.wosid | WOS:000401571500001 | * |
dc.identifier.scopusid | 2-s2.0-85018393493 | * |
dc.author.google | Bousquet J. | * |
dc.author.google | Barnes N. | * |
dc.author.google | Gibbs M. | * |
dc.author.google | Gul N. | * |
dc.author.google | Tomkins S.A. | * |
dc.author.google | Zhou X. | * |
dc.author.google | Cho Y.-J. | * |
dc.author.google | Park H.-S. | * |
dc.author.google | Busse W. | * |
dc.author.google | Zhong N. | * |
dc.contributor.scopusid | 조영주(55472202600;56657140200) | * |
dc.date.modifydate | 20240118125203 | * |